Ropes & Gray represented Prilenia Therapeutics in a licensing agreement with Ferrer Internacional under which Ferrer would obtain rights to develop, manufacture, and commercialize Prilenia’s pre-commercial sigma-1 receptor agonist Pridopidine for neurodegenerative diseases in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. The transaction was announced on April 28.
Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on net sales.
The Ropes & Gray team was led by life sciences licensing partner Abby Gregor and life sciences licensing associate Evan Tallmadge.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.